Education

Apr 01, 2025

Associations of moderate alcohol intake with cerebrospinal fluid biomarkers of Alzheimer’s disease: data from the ALBION study

Mar 31, 2025

Age as a limiting factor for effectiveness of photostimulation of brain drainage and cognitive functions

Mar 31, 2025

N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy

Mar 26, 2025

Emerging biophysical origins and pathogenic implications of amyloid oligomers

Mar 24, 2025

Anti‐amyloid treatments: Why we think they are worth it

Mar 22, 2025

Protocol of the follow-up of patients with transthyretin amyloid cardiomyopathy by multimodality imaging (FAITH) study: a prospective observational study in patients with ATTR-CM undergoing treatment with tafamidis

Mar 21, 2025

Integrated specialty care for amyloidosis: a scoping review using the Consolidated Framework for Implementation Research

Mar 12, 2025

A rare presentation of pulmonary transthyretin amyloidosis

Mar 10, 2025

Diagnosis and management of mixed-phenotype hereditary-transthyretin amyloidosis: A case-based, Canadian perspective

Mar 07, 2025

Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting

Subscribe to

Newsletter

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.